Future care for long-term cancer survivors: towards a new model

• DOI: 10.1007/s12094-021-02696-5
• Publication Date: 2021-10-29T17:02:50Z
• Authors: M. Provencio; N. Romero; J. Tabernero; R. Vera; D. V. Baz; A. Arraiza; C. Camps; E. Felip; P. Garrido; B. Gaspar; M. Llombart; A. López; I. Magallón; V. M. Ibáñez; J. M. Olmos; C. Mur; A. Navarro-Ruiz; A. Pastor; M. Peiró; J. Polo; Á. Rodríguez-Lescure
• Keywords: Medicina - Presa de decisions; LCS patient care; Delphi Technique; Medicina; Càncer - Tractament; Otros calificadores::Otros calificadores::Otros calificadores::/terapia; Models, Theoretical; Medical Oncology; 3. Good health; DISEASES::Neoplasms; 03 medical and health sciences; 0302 clinical medicine; Cancer Survivors; ENFERMEDADES::neoplasias; Spain; Neoplasms; Humans; Other subheadings::Other subheadings::Other subheadings::/therapy; Multidisciplinary cancer care; Long cancer survivor; Research Article

Abstract Purpose The increase in the prevalence "long-term cancer survivor” (LCS) patients is expected to increase the cost of LCS care. The aim of this study was to obtain information that would allow to optimise the current model of health management in Spain to adapt it to one of efficient LCS patient care.

Methods This qualitative study was carried out using Delphi methodology. An advisory committee defined the criteria for participation, select the panel of experts, prepare the questionnaire, interpret the results and draft the final report.

Results 232 people took part in the study (48 oncologists). Absolute consensus was reached in three of the proposed sections: oncological epidemiology, training of health professionals and ICT functions.

Conclusion The role of primary care in the clinical management of LCS patients needs to be upgraded, coordination with the oncologist and hospital care is essential. The funding model needs to be adapted to determine the funding conditions for new drugs and technologies.